Ramin Mojdeh, Ph.D. Executive Vice President and Chief Operating Officer UBS Specialty Pharma Conference May 2011

1. Innovative Drug Delivery Device Solutions Ramin Mojdeh, Ph.D. Executive Vice President and Chief Operating Officer UBS Specialty Pharma Conference May 2011

2. Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However you should not place undue reliance on any such forward looking statements as these are subject to risks and uncertainties. Please refer to our press release and our SEC filings for more information regarding the use of forward looking statements. 2

4. Enable and enhance delivery of drugs by pharmaceutical customers

5. Rapidly expanding pipeline being driven by customer needs

6. Unifill– world’s only prefilled platform with integrated safety

7. NASDAQ listed (UNIS) with state-of-the-art facility in York, PA3

9. Large macromolecule composition of pharmaceutical pipeline

10. Safety legislation and sharps management

11. Devices drive patient acceptance, preference and adherence

12. Emerging healthcare needs of aging global population

13. Risingglobalhealthcarestandardscreatingstrongmarketpotential

14. Improved outcomes and economics with use of unit-dose and ready to administer formats

15. Trend to patients self-administration of injectable drugs

16. Patent cliff - 30 biologics with $51B sales expire by 20154

18. Integratedproprietaryprimarydrug delivery devices withvalue-addfeatures

19. Target and address emerging unmet needs for pipeline drugs

20. Pharmaceuticalcollaborations – specializeddevicesfornoveldrugs

21. Targethigh-endofmarketfordifferentiateddevices, highmargins

22. Strategic sourcing of components

23. In-house manufacturing and final assembly5

25. Directly responding to emerging customer needs including:

26. Integrated primarydrugdelivery devices withvalue-addfeaturesandcustomization

27. Advanced syringe systems with integrated safety and transfer mechanisms

28. Dry drug reconstitution and delivery technologies

29. Large-volume viscous drugs delivery technologies

30. Targeted organ delivery devices

31. Multi-chamber proprietary primary containers and delivery systems

32. Reusable and disposable self administration device technologies

33. Technology portfolio can be leveraged to develop customized device concepts according to specific customer needs6

35. Now in production

36. Controlled retraction into barrel

38. Direct substitute for current prefill and safety prefill syringes

39. Powerful brand differentiation

40. Streamlines fill-finish and packaging process

41. Optimal protection2.5B Units Annually Ancillary safety needle + Unifill Platform Standard Prefill Syringe Current Safety Syringe Direct Substitute Ancillary safety Device + Standard Prefill Syringe Current Safety Syringe 8

42. 9 Success in the Face of a Big Challenge Technologysolvesatechnicalchallengemostthoughtimpossible Sanofi invested $40MM for access rights to Unifill Ready for initial shipment in July – well ahead of original schedule Current capacity of 60MM units, planned 150MM unit line extension

44. Collaboration with drug companies from clinical development through commercial sales

46. Injectable drug delivery device market is attractive and growing fast

47. Innovative, differentiated devices for pipeline drugs and biosimilars

48. Developing rich portfolio of technologies driven by customer need

49. Unifill: the 1st and only prefill syringe system with integrated safety

50. The new drug-device paradigm is to target pipeline drugs to develop total system solutions for the pharmaceutical partner

51. LaunchwithUnifill,thendrivegrowthwithsuccessive introductionsofinnovative,differentiateddevices